Asia-Pacific Bioinformatics Market

The APAC bioinformatics market is expected to grow from US$ 2,887.82 million in 2022 to US$ 7,121.68 million by 2028; it is estimated to grow at a CAGR of 16.2% from 2022 to 2028. 

Integration of Artificial Intelligence (AI) and Machine Learning in Bioinformatics To Drive Market Growth 

Bioinformatics and AI play critical roles in changing and advancing the healthcare industry. In the context of bioinformatics, AI can be used to promote clinical research and analysis that can result in the design of new drugs and vaccines, the diagnosis of diseases, and even the prediction of pandemics. For example, AI can be used in conjunction with bioinformatics in wearable tech. Consumers are already familiar with many types of wearable techs, such as fitness trackers and watches, and make personal use of the data they collect. The wearable tech provides real-time data over a period and can help track trends and identify signs of potentially fatal health issues, such as heart disease, much quicker and more accurately than spot tests conducted in laboratories. Also, genome sequencing plays a pivotal role in medical diagnostics. Machine learning-empowered DNA sequencing techniques such as next-generation sequencing have made it possible for researchers to sequence human genomes within a day compared to the traditional sanger sequencing technology, which took over a decade to sequence a human genome. Thus, the integration of AI and machine learning in bioinformatics is expected to fuel the bioinformatics market over the forecast period. 

Market Overview 

The APAC bioinformatics market is segmented into China, India, Japan, South Korea, Australia, and Rest of APAC. China dominated the market in 2022. In China, the demand for genetic sequencing is fueled by the country’s growing middle class, aging population, and expanding healthcare system. Many companies are investing significant amounts into genetics research in the country. For instance, in January 2021, Illumina partnered with Sequoia Capital’s China-based subsidiary to launch a new incubator for genomics start-ups. Illumina will provide sequencing systems, reagents, and genomics expertise and will help outfit laboratory space, while the investment firm will help connect new companies and founders with entrepreneurs and financial advice, as well as provide approximately US$ 500,000 in upfront funding. Also, biotechnology is set to become a key driver of economic and social development in China, increasing the adoption of genomics. The local giant BGI Group is expanding its foothold in the gene-sequencing industry. The company has sold 35 million rapid COVID-19 testing kits to 180 countries and built 58 labs in 18 countries. The Chinese genomics industry is acquiring technologies crucial to advancement in the field to develop the infrastructure for genomics. For instance, in June 2020, Personalis, Inc., a leader in advanced genomics for cancer, partnered with Berry Genomics (China). Personalis is expanding its business operations in China with plans to form a fully-owned subsidiary in Shanghai. The expansion will include building a laboratory operation for local customers to use its ImmunoID NeXT PlatformTM, a commercial team to support local customers, and general and administrative functions. Also, owing to the growing advancements aided by government support, precision medicine research is proliferating in the region. For instance, in July 2018, GE Healthcare opened the GE Cell and Gene Therapy Asia Technology Center to train thousands of scientists in precision medicine-driven biopharma techniques. Further, 11 Chinese companies are using its biopharma production process, FlexFactory. Various strategic initiatives such as acquisitions, partnerships, and collaborations bolstered the growth of the country's market. For instance, in November 2020, Congenica, one of the UK's fastest-growing genomics companies, sold its stake to Tencent, a Chinese company, as part of the funding. Thus, owing to these advancements, the bioinformatics market is expected to grow at a rapid pace over the forecast period. 

APAC Bioinformatics Market Revenue and Forecast to 2028 (US$ Million) 

APAC Bioinformatics Market Segmentation 

The APAC bioinformatics market is segmented based on product, application, sector, and country. 

Based on product, the APAC bioinformatics market is segmented into knowledge management tools, bioinformatics platforms, and bio informative services. The bioinformatics platforms segment held the largest market share in 2022. Based on application, the APAC bioinformatics market is segmented into genomics, chemo informatics and drug design, proteomics, transcriptomics, metabolomics, and others. The genomics segment held the largest market share in 2022. Based on sector, the APAC bioinformatics market is segmented into medical biotechnology, academics, animal biotechnology, agricultural biotechnology, environmental biotechnology, forensic biotechnology, and others. The medical biotechnology segment held the largest market share in 2022. Based on country, the APAC bioinformatics market has been categorized into China, India, Japan, South Korea, Australia, and Rest of APAC. Further, China dominated the market in 2022. Agilent Technologies, Inc.; Bruker Corporation; Dassault Systèmes; Eurofins Scientific; Illumina, Inc.; PerkinElmer Inc.; QIAGEN; and Thermo Fisher Scientific Inc. are the leading companies operating in the APAC bioinformatics market

Asia-Pacific Bioinformatics Market Strategic Insights

Asia-Pacific Bioinformatics Market Segmentation Analysis

Asia-Pacific Bioinformatics Market Report Highlights

Asia-Pacific Bioinformatics Report Scope

Asia-Pacific Bioinformatics Market Country and Regional Insights